Deborah Lindquist - Concepedia

Concepedia

Author

Deborah Lindquist

Also Known As

D Lindquist, D. L. Lindquist, D.L. Lindquist, Deborah L Lindquist, Deborah L. Lindquist, Deborah Lindquist

36

Publications

5.4K

Citations

12

H-Index

17

Concepts

All Affiliations

Texas Oncology Arizona Oncology GlaxoSmithKline (United States)The University of Texas MD Anderson Cancer Center Rigshospitalet

DL

About

Deborah Lindquist is an author at Texas Oncology specializing in cancer therapeutics, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.6K
2	Health Sciences	3	3	634
3	Pharmacology	2	2	840
4	Immunology	1	1	39
5	Pathology	1	1	801

Deborah Lindquist

×

12

Publications

5.4K

Citations

12

H-Index

	Year	Citations
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Charles E. Geyer, John Forster, Deborah Lindquist, New England Journal of Medicine	2006	3.4K
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses David Cameron, Michelle Casey, Michael F. Press, Breast Cancer Research and Treatment Breast OncologyOncologyMedicinePhase IiiCapecitabine Versus Capecitabine	2008	801
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study Stephen E. Jones, Rufus Collea, Devchand Paul, The Lancet Oncology	2013	134
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial Paul E. Goss, Ian E. Smith, Joyce O’Shaughnessy, The Lancet Oncology Breast OncologyAdjuvant LapatinibMedicineBreast CancerCancer Treatment	2012	130
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial Joyce O’Shaughnessy, Katarína Petráková, Gabe S. Sonke, Breast Cancer Research and Treatment	2017	108
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy Linda T. Vahdat, Agustin A. García, Charles L. Vogel, Breast Cancer Research and Treatment	2013	66
Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer Joyce O’Shaughnessy, D Paul, Christopher Stokoe, Cancer Research Breast OncologyPrimary EndpointImmunologyPharmacotherapyImmunotherapeutics	2010	39
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy Kathrin Strasser‐Weippl, Nora Horick, Ian E. Smith, Breast Cancer Research	2015	36
Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer David Loesch, F. Anthony Greco, Neil Senzer, Journal of Clinical Oncology	2010	24

Page 1